The price of Tresiba (insulin degludec) can vary significantly based on factors such as dosage, quantity, insurance coverage, and pharmacy. Without insurance, a 10-mL vial of Tresiba U-100 can range from approximately $275 to $315. A 3-pen pack of Tresiba U-100 is often priced between $300 and $350. These prices are estimates and can differ by location and specific retail outlet.
How much does Tresiba cost with insurance?
Insurance coverage for Tresiba is a critical factor in its affordability. Many insurance plans offer a tiered formulary, which affects the out-of-pocket cost. For individuals with good prescription drug coverage, the copay for Tresiba might be significantly lower, potentially ranging from $10 to $50 per prescription. However, patients may still encounter higher costs if Tresiba is not on their plan's preferred formulary or if they have a high-deductible health plan. Checking with the specific insurance provider is essential to understand individual coverage and copayments.
Are there ways to get Tresiba for less?
Several avenues can help reduce the cost of Tresiba. Discount cards and manufacturer coupons are often available and can lower the out-of-pocket expense for both insured and uninsured patients. For example, Novo Nordisk, the manufacturer of Tresiba, offers a Tresiba Savings Card that can reduce the monthly cost for eligible patients. Additionally, comparing prices across different pharmacies, including local drugstores and online pharmacies, can reveal cost savings. Some patient assistance programs may also be available for those who meet certain financial eligibility criteria.
When does Tresiba's patent expire?
The patent landscape for Tresiba is complex and can impact future pricing and the availability of generic alternatives. Information regarding specific patent expiry dates for Tresiba can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides details on patents and exclusivity periods for various medications, which can help in understanding when market exclusivity for Tresiba might end [1].
What are Tresiba's competitors?
Tresiba is a long-acting insulin used for the treatment of type 1 and type 2 diabetes. It competes with other long-acting insulin products available on the market. These competitors include other insulin degludec formulations, as well as insulins like insulin glargine (e.g., Lantus, Basaglar) and insulin detemir (e.g., Levemir). The choice between these insulins often depends on individual patient needs, physician recommendations, and cost-effectiveness.
What is Tresiba used for?
Tresiba is a long-acting basal insulin used to improve glycemic control in adults and children aged one year and older with diabetes mellitus. It is administered once daily and helps to provide a steady level of insulin throughout the day and night. It is used for both type 1 and type 2 diabetes, where it complements the action of prandial (mealtime) insulin or oral diabetes medications.
Sources:
[1] DrugPatentWatch.com